Pre-Made Romiplostim Biosimilar, Fusion Protein targeting MPL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting C-MPL/CD110/MPLV/THCYT2/THPOR/TPOR is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Romiplostim is a fusion protein of thrombopoietin (TPO) peptide analog with Fc-peptide (peptibody) to increase platelet production through activation of the thrombopoietin receptor. It is used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).